Tillotts markets its own products such as Asacol™ and Entocort™ as well as in-licensed products in around 50 countries through its affiliates within Europe and a network of gastroenterology-focused partners throughout the world. As a Zeria subsidiary, Tillotts leverages its parent company's resources and global reach to expand its specialty gastrointestinal pharmaceutical portfolio across multiple markets. The company focuses on therapeutic areas including inflammatory bowel disease, Clostridioides difficile infection, and other gastrointestinal conditions.
Cyborg Score Rationale
Tillotts demonstrates solid market positioning in the specialty gastroenterology pharmaceutical segment with established product lines and presence in approximately 50 countries. As a Zeria subsidiary since 2009, it benefits from parent company backing and stable operations. However, as a private company with limited public disclosure, growth trajectory and competitive dynamics are harder to assess compared to public peers.
Top Insights
Gastroenterology focus provides defensible niche market positioning with strong clinical relationships and repeat prescriber base
International footprint spanning 50+ countries leverages in-licensing business model for rapid market entry without extensive R&D costs
Zeria Group backing provides capital, regulatory expertise, and Asian market access for product expansion and portfolio diversification
Flagships Asacol™ and Entocort™ represent established branded products with known efficacy in inflammatory bowel disease treatment
Named Competitors
Gastroenterology pharmaceuticals — Specialty pharma focused on gastroenterology and other therapeutic areas
GI pharmaceuticals — Swiss-based gastroenterology pharmaceutical company
Recent Developments
(July 2021) Launched Asacol 800 mg tablets in China for mild to moderate ulcerative colitis treatment
(November 2020) Acquired rights to DIFICLIR™ (fidaxomicin) from Astellas Pharma for Europe, Middle East, Africa, Russia and select CIS countries
(September 2022) Selected Veeva CRM and Veeva Vault PromoMats to build unified commercial platform
Open the full interactive Tillotts Pharma AG report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.